A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2 inhibitor empagliflozin

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins) are associated with lower all-cause mortality than other anti-diabetic agents in patients with type 2 diabetes. In patients who may benefit from SGLT2is, but cannot add them to a dipeptidyl peptidase-4 inhibitor (DPP4i, glip...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chung-Huei, Huang, Yu-Yao, Hsu, Brend Ray-Sea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302983/
https://www.ncbi.nlm.nih.gov/pubmed/30531176
http://dx.doi.org/10.5144/0256-4947.2018.420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302983/
https://www.ncbi.nlm.nih.gov/pubmed/30531176
http://dx.doi.org/10.5144/0256-4947.2018.420

Ejemplares similares